Home › Castration-Resistant Prostatic Cancer › Washington
Castration-Resistant Prostatic Cancer clinical trials in Washington, DC
3 studies for Castration-Resistant Prostatic Cancer are looking for participants at sites in and around Washington (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
RecruitingPhase 3
- Johns Hopkins Office of Capital Region Research - Sibley Memorial Hospital, Washington D.C.
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
RecruitingPhase 3
- Center for Cancer and Blood Disorders, Bethesda · 7 mi away
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
RecruitingPhase 1/2
- MedStar Georgetown Cancer Institute at MedStar Washington Hospital Center ( Site 0026), Washington D.C.
Castration-Resistant Prostatic Cancer trials in other cities
- Los Angeles, CA7 studies
- Houston, TX6 studies
- New York City, NY6 studies
- Seattle, WA6 studies
- Boston, MA5 studies
- Queens, NY4 studies
- Pittsburgh, PA4 studies
- Philadelphia, PA4 studies
- San Francisco, CA4 studies
- Nashville, TN3 studies
- Cincinnati, OH3 studies
- Minneapolis, MN3 studies
Other studies in Washington
- Cancer (all types)60 studies
- Non-Small Cell Lung Cancer55 studies
- Breast Cancer44 studies
- Metastatic Cancer44 studies
- Lung Cancer41 studies
- Prostate Cancer39 studies
- Obesity34 studies
- Colorectal Cancer28 studies
- Cardiovascular Disease27 studies
- Bladder Cancer26 studies
- Ovarian Cancer25 studies
- Lymphoma23 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.